<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920972</url>
  </required_header>
  <id_info>
    <org_study_id>201110144</org_study_id>
    <nct_id>NCT00920972</nct_id>
  </id_info>
  <brief_title>Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases</brief_title>
  <official_title>A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Louis Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis for this study is that a preparative regimen that maximizes host
      immunosuppression without myeloablation will be well tolerated and sufficient for engraftment
      of donor hematopoietic cells. It is also to determine major toxicities from these
      conditioning regimens, within the first 100 days after transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Donor engraftment as measured by chimerism</measure>
    <time_frame>100 days post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major toxicities as graded by the CTC v4</measure>
    <time_frame>100 days post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil and platelet engraftment as measured by complete blood counts</measure>
    <time_frame>Notapplicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host disease as measured by protocol grading scale</measure>
    <time_frame>100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease as measured by protocol grading scale</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term donor engraftment by donor chimerism</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution by laboratory evaluations</measure>
    <time_frame>1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease free survival</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Metabolic Disorders</condition>
  <condition>Hematologic, Immune, or Bone Marrow Disorders</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Non-malignant Disorders</condition>
  <arm_group>
    <arm_group_label>Matched related HSCT for hemoglobinopathies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Unrelated HSCT for thalassemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimally mismatched unrelated HSCT for hemoglobinopathies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minor mismatched unrelated HSCT for non-malignant disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan</intervention_name>
    <description>Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients &lt;10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
GVHD Prophylaxis:
Starting day -3: Tacrolimus or cyclosporine... Days +1, +3, +6: Methotrexate</description>
    <arm_group_label>Matched related HSCT for hemoglobinopathies</arm_group_label>
    <other_name>Alemtuzumab</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, &amp; melphalan</intervention_name>
    <description>Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients &lt;10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Options:
Regimen 1= Starting day -3: Tacrolimus or cyclosporine... Days +1, +3, +6: Methotrexate.... Starting on day +7: Prednisone...
OR Regimen 2 = Starting day -3: tacrolimus or cyclosporine Starting day -3: mycophenolate mofetil</description>
    <arm_group_label>Unrelated HSCT for thalassemia</arm_group_label>
    <other_name>Alemtuzumab</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, &amp; melphalan</intervention_name>
    <description>Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IVor SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients &lt;10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Regimen:
Children &lt; 6 years of age, BM recipients:
Regimen 1 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Starting day +7: prednisone...
Children &gt;/=6 years, BM recipients:
Regimen 3 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Days -1, +5, +14, +28: abatacept...
UCB recipients:
Regimen 1 (described above) OR Regimen 2 = Starting day -3: tacro or CsA... Starting day -3: MMF</description>
    <arm_group_label>Minimally mismatched unrelated HSCT for hemoglobinopathies</arm_group_label>
    <other_name>Alemtuzumab</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, &amp; melphalan</intervention_name>
    <description>Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients &lt;10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Regimen:
Children &lt; 6 years of age, BM recipients:
Regimen 1 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Starting day +7: prednisone...
Children &gt;/=6 years, BM recipients:
Regimen 3 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Days -1, +5, +14, +28: abatacept...
UCB recipients:
Regimen 1 (described above) OR Regimen 2 = Starting day -3: tacro or CsA... Starting day -3: MMF</description>
    <arm_group_label>Minor mismatched unrelated HSCT for non-malignant disorders</arm_group_label>
    <other_name>Alemtuzumab</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Stratum 1: Patient must have a hemoglobinopathy receiving a matched related transplant with
        bone marrow or peripheral blood stem cells.

        Stratum 2: Patient must have thalassemia receiving an unrelated donor transplant with bone
        marrow or umbilical cord blood stem cells.

        Stratum 3: Patient must have a hemoglobinopathy receiving a minimally mismatched unrelated
        donor transplant with bone marrow or single or double umbilical cord blood product.

        Stratum 4: Patient must have a non-malignant disorder (excluding hemoglobinopathy)
        receiving a minor mismatched unrelated donor transplant with bone marrow or single or
        double umbilical cord blood product.

        All strata:

          -  Recipient age &lt; 21 years

          -  Lansky/Karnofsky &gt;/= 40

          -  Adequate pulmonary, renal, liver, and other organ function as defined in protocol

          -  Negative pregnancy test

          -  Adequate total nucleated cell or CD34+ dose of product as defined in protocol

          -  If sickle cell, Hemoglobin S &lt;45%

        Exclusion Criteria:

          -  HIV positive

          -  Invasive infection

          -  Pregnancy/lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalini Shenoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine (in St. Louis)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Murray, MA, CCRP</last_name>
    <phone>3144544240</phone>
    <email>Murray_L@kids.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberta Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Washington University School of Medicine</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Jacobsohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Andreansky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kamar Godder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gregory Hale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sonali Chaudhury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Haut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lolie Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jignesh Dalal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepika Bhatla, MD</last_name>
    </contact>
    <investigator>
      <last_name>Deepika Bhatla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine (in St. Louis)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini Shenoy, MD</last_name>
      <phone>314-454-6018</phone>
      <email>shenoy@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Murray, MA, CCRP</last_name>
      <phone>3144544240</phone>
      <email>Murray_L@kids.wustl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfred Gillio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Bhatia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Monica Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Eckrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suhag Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Troy Quigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0W3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Guilcher, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gregory Guilcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bhatla D, Davies SM, Shenoy S, Harris RE, Crockett M, Shoultz L, Smolarek T, Bleesing J, Hansen M, Jodele S, Jordan M, Filipovich AH, Mehta PA. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008 Aug;42(3):159-65. doi: 10.1038/bmt.2008.151. Epub 2008 May 26.</citation>
    <PMID>18500373</PMID>
  </results_reference>
  <results_reference>
    <citation>Hansen MD, Filipovich AH, Davies SM, Mehta P, Bleesing J, Jodele S, Hayashi R, Barnes Y, Shenoy S. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008 Feb;41(4):349-53. Epub 2007 Nov 19.</citation>
    <PMID>18026148</PMID>
  </results_reference>
  <results_reference>
    <citation>Rao A, Kamani N, Filipovich A, Lee SM, Davies SM, Dalal J, Shenoy S. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood. 2007 Jan 1;109(1):383-5. Epub 2006 Sep 21.</citation>
    <PMID>16990602</PMID>
  </results_reference>
  <results_reference>
    <citation>Shenoy S, Grossman WJ, DiPersio J, Yu LC, Wilson D, Barnes YJ, Mohanakumar T, Rao A, Hayashi RJ. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005 Feb;35(4):345-52.</citation>
    <PMID>15592491</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone marrow</keyword>
  <keyword>Transplant</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Hematopoietic</keyword>
  <keyword>Umbilical cord</keyword>
  <keyword>Related</keyword>
  <keyword>Unrelated</keyword>
  <keyword>Reduced</keyword>
  <keyword>Non-myeloablative</keyword>
  <keyword>Nonmyeloablative</keyword>
  <keyword>Non-malignant</keyword>
  <keyword>Nonmalignant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

